AR123646A1 - Virus de la diarrea epidémica porcina atenuado - Google Patents
Virus de la diarrea epidémica porcina atenuadoInfo
- Publication number
- AR123646A1 AR123646A1 ARP210102711A ARP210102711A AR123646A1 AR 123646 A1 AR123646 A1 AR 123646A1 AR P210102711 A ARP210102711 A AR P210102711A AR P210102711 A ARP210102711 A AR P210102711A AR 123646 A1 AR123646 A1 AR 123646A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- acid sequence
- pedv
- amino acid
- deletion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una proteína espicular truncada en el terminal C de PEDV caracterizada porque carece de SEQ ID Nº 1 (YEVFEKVHVQ) o una secuencia que comprende SEQ ID Nº 1 y que comprende una secuencia de aminoácidos que es al menos 90% idéntica a SEQ ID Nº 2 o una variante truncada en el terminal C de esta, con la condición de que dicha proteína espicular truncada en el terminal C de PEDV tenga una longitud de al menos 1200 aminoácidos. Reivindicación 8: Una secuencia de ácidos nucleicos caracterizada porque codifica la proteína espicular truncada en el terminal C de acuerdo con cualquiera de las reivindicaciones 1 - 7. Reivindicación 9: Un virus caracterizado porque comprende la proteína espicular truncada en el terminal C de acuerdo con cualquiera de las reivindicaciones 1 - 7 o la secuencia de ácidos nucleicos de acuerdo con la reivindicación 8. Reivindicación 10: Una secuencia de aminoácidos caracterizada porque comprende SEQ ID Nº 3 o una secuencia que es al menos 90% idéntica a esta, con la condición de que los aminoácidos del terminal C de dicha SEQ ID Nº 3 sean QPLAL (SEQ ID Nº 4). Reivindicación 16: Una secuencia de aminoácidos caracterizada porque comprende SEQ ID Nº 5. Reivindicación 17: Un virus caracterizado porque tiene un genoma que comprende un ORF que codifica la secuencia de aminoácidos de acuerdo con la reivindicación 16. Reivindicación 19: Un PEDV que comprende ORF-2 y ORF-3, caracterizado por la condición de que el virus comprenda una primera eliminación en dicho ORF2 / ORF3, en donde dicha primera eliminación es una eliminación de SEQ ID Nº 6 o una eliminación de una secuencia de ácidos nucleicos que comprende SEQ ID Nº 6, con la condición de que dicho virus exprese una secuencia de aminoácidos que comprende SEQ ID Nº 3 o una secuencia que es al menos 90% idéntica a esta, con la condición adicional de que los aminoácidos del terminal C de dicha SEQ ID Nº 3 sean QPLAL (SEQ ID Nº 4). Reivindicación 27: Un PEDV atenuado adicional caracterizado porque es una progenie del PEDV parental de acuerdo con la reivindicación 24. Reivindicación 29: Una vacuna caracterizada porque comprende el PEDV de acuerdo con cualquiera de las reivindicaciones 18 - 26 o el PEDV atenuado adicional de acuerdo con la reivindicación 27 o la reivindicación 28.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011048314.0A CN114315985A (zh) | 2020-09-29 | 2020-09-29 | 减毒猪流行性腹泻病毒 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR123646A1 true AR123646A1 (es) | 2022-12-28 |
Family
ID=78372132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210102711A AR123646A1 (es) | 2020-09-29 | 2021-09-29 | Virus de la diarrea epidémica porcina atenuado |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP4221748A2 (es) |
JP (1) | JP2023543033A (es) |
KR (1) | KR20230079021A (es) |
CN (2) | CN114315985A (es) |
AR (1) | AR123646A1 (es) |
AU (1) | AU2021353430A1 (es) |
BR (1) | BR112023005715A2 (es) |
CA (1) | CA3197074A1 (es) |
CL (1) | CL2023000913A1 (es) |
CO (1) | CO2023004100A2 (es) |
EC (1) | ECSP23029637A (es) |
MX (1) | MX2023003651A (es) |
PE (1) | PE20240081A1 (es) |
TW (1) | TW202221012A (es) |
WO (1) | WO2022072215A2 (es) |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3137631A (en) | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
US3959457A (en) | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US3914408A (en) | 1973-10-12 | 1975-10-21 | Univ Nebraska | Vaccine for neonatal calf diarrhea |
JPS5186117A (en) | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
US4205060A (en) | 1978-12-20 | 1980-05-27 | Pennwalt Corporation | Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use |
US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
US4744933A (en) | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4606940A (en) | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
US5009956A (en) | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
JP3011939B2 (ja) | 1987-03-02 | 2000-02-21 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 組換えミコバクテリア・ワクチン |
US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5132117A (en) | 1990-01-11 | 1992-07-21 | Temple University | Aqueous core microcapsules and method for their preparation |
JPH05504067A (ja) | 1990-02-26 | 1993-07-01 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | 大腸菌及びマイコバクテリアのためのシャトルプラスミド |
GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
CA2110682A1 (en) | 1991-06-06 | 1992-12-10 | Charles K. Stover | Induction of ctl responses to foreign antigens expressed in mycobacteria |
ATE235959T1 (de) | 1994-04-15 | 2003-04-15 | Univ Temple | Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
CN1688606A (zh) | 2002-08-12 | 2005-10-26 | 昆士兰医学研究所理事会 | 含有辅助t细胞和b细胞表位的新的免疫原性脂肽 |
CN1688605B (zh) | 2002-08-12 | 2011-01-12 | 昆士兰医学研究所理事会 | 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽 |
WO2004026024A2 (en) | 2002-09-20 | 2004-04-01 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine compositions and adjuvant |
KR20080013850A (ko) | 2005-02-08 | 2008-02-13 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 면역원성 분자 |
WO2007127936A2 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
GB2552441A (en) * | 2015-10-22 | 2018-01-31 | Royal Veterinary College | Methods |
-
2020
- 2020-09-29 CN CN202011048314.0A patent/CN114315985A/zh active Pending
-
2021
- 2021-09-23 WO PCT/US2021/051807 patent/WO2022072215A2/en active Application Filing
- 2021-09-23 BR BR112023005715A patent/BR112023005715A2/pt unknown
- 2021-09-23 EP EP21798526.6A patent/EP4221748A2/en active Pending
- 2021-09-23 PE PE2023001249A patent/PE20240081A1/es unknown
- 2021-09-23 CN CN202180061801.7A patent/CN116635521A/zh active Pending
- 2021-09-23 JP JP2023519275A patent/JP2023543033A/ja active Pending
- 2021-09-23 KR KR1020237007715A patent/KR20230079021A/ko active Search and Examination
- 2021-09-23 AU AU2021353430A patent/AU2021353430A1/en active Pending
- 2021-09-23 MX MX2023003651A patent/MX2023003651A/es unknown
- 2021-09-23 CA CA3197074A patent/CA3197074A1/en active Pending
- 2021-09-27 TW TW110135848A patent/TW202221012A/zh unknown
- 2021-09-29 AR ARP210102711A patent/AR123646A1/es unknown
-
2023
- 2023-03-29 CO CONC2023/0004100A patent/CO2023004100A2/es unknown
- 2023-03-29 CL CL2023000913A patent/CL2023000913A1/es unknown
- 2023-04-24 EC ECSENADI202329637A patent/ECSP23029637A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112023005715A2 (pt) | 2023-05-02 |
JP2023543033A (ja) | 2023-10-12 |
CO2023004100A2 (es) | 2023-04-05 |
CN114315985A (zh) | 2022-04-12 |
CL2023000913A1 (es) | 2023-11-24 |
EP4221748A2 (en) | 2023-08-09 |
PE20240081A1 (es) | 2024-01-16 |
AU2021353430A1 (en) | 2023-05-11 |
MX2023003651A (es) | 2023-04-19 |
WO2022072215A2 (en) | 2022-04-07 |
TW202221012A (zh) | 2022-06-01 |
AU2021353430A9 (en) | 2024-01-18 |
WO2022072215A3 (en) | 2022-07-07 |
CN116635521A8 (zh) | 2023-11-03 |
ECSP23029637A (es) | 2023-07-31 |
CN116635521A (zh) | 2023-08-22 |
CA3197074A1 (en) | 2022-04-07 |
KR20230079021A (ko) | 2023-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sánchez et al. | Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-directed mutagenesis | |
Mason et al. | Biochemical mapping of the simian rotavirus SA11 genome | |
CL2020002201A1 (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidación reducida de la cápside y usos de estos. | |
ES2150416T3 (es) | Vacuna virica defectiva producida por una linea celular complementada en trans. | |
ES2570758T3 (es) | Materiales y métodos para el control de enfermedades respiratorias en cánidos | |
DK0596979T3 (da) | Rekombinante nucleinsyrer fra plantevirus | |
PE20010704A1 (es) | Composicion farmaceutica que comprende un antigeno | |
NO20052149L (no) | Polynukleotidvaksine omfattende sekvens som koder for hepatitt C-virus protein. | |
AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
RU2011130829A (ru) | Рекомбинантный вирус классической чумы свиней (csfv), содержащий модифицированный белок е2, и способы создания указанного рекомбинантного csfv | |
AR056133A1 (es) | Virus de influenza canina y composiciones relacionadas y metodos de uso | |
MX9202512A (es) | Virus de avipox recombinante, cultivo de celulas infectadas por este virusy vacunas para las aves de corral derivadas de este virus. | |
AR123646A1 (es) | Virus de la diarrea epidémica porcina atenuado | |
AR124461A1 (es) | VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2 | |
Xu et al. | Sequencing and comparative analysis of a pig bovine viral diarrhea virus genome | |
AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
AR116876A1 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv | |
PH12020551944A1 (en) | Reverse peptide vaccine | |
ES2077017T3 (es) | Vacuna contra el virus de la bronquitis infecciosa. | |
AR124651A1 (es) | Vectores de aav dirigidos a linfocitos t | |
UY30602A1 (es) | Mutante de un pestivirus, vacuna y aplicaciones | |
ES2531098T3 (es) | Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg) | |
RU2253870C1 (ru) | РЕКОМБИНАНТНЫЕ БЕЛКИ, СОДЕРЖАЩИЕ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ЭПИТОПЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ, И ПОСЛЕДОВАТЕЛЬНОСТИ СИНТЕТИЧЕСКИХ ГЕНОВ, КОДИРУЮЩИХ ДИАГНОСТИЧЕСКИ ЗНАЧИМЫЕ АНТИГЕННЫЕ ДЕТЕРМИНАНТЫ БЕЛКОВ КОРОНАВИРУСА (SARS-CoV), СВЯЗАННОГО С ТЯЖЕЛЫМ ОСТРЫМ РЕСПИРАТОРНЫМ СИНДРОМОМ | |
Salarpour et al. | Nucleotide Sequence Analysis of S1 Gene among Iranian Avian Infectious Bronchitis Viruses Isolated during 2001-2002 |